Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenomics.

E B Binder1, F Holsboer

  • 1Max-Planck Institute of Psychiatry, Kraepelinstr. 10, 80804 Munich, Germany.

Handbook of Experimental Pharmacology
|April 6, 2006
PubMed
Summary
This summary is machine-generated.

Pharmacogenetic studies show promise for anxiety disorder treatment. Future research could personalize antidepressant selection based on genetic factors, improving efficacy and reducing side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Developmental Correlates of Epigenetic and Polygenic Indices of Cognition and Educational Attainment from Birth to Young Adulthood.

bioRxiv : the preprint server for biology·2026
Same author

Functional polygenic risk score of glucocorticoid-dependent regulatory element activity and its relation to clinical and stress-related phenotypes.

Psychoneuroendocrinology·2025
Same author

Insights from a methylome-wide association study of antidepressant exposure.

Nature communications·2025
Same author

Antidepressant Exposure and DNA Methylation: Insights from a Methylome-Wide Association Study.

medRxiv : the preprint server for health sciences·2024
Same author

Genome-wide gene expression in a pharmacological hormonal transition model and its relation to depressive symptoms.

Acta psychiatrica Scandinavica·2019
Same author

An epigenome-wide association study meta-analysis of educational attainment.

Molecular psychiatry·2017

Area of Science:

  • Pharmacogenomics
  • Psychiatry
  • Genetics

Background:

  • No pharmacogenetic studies specifically target anxiety disorders.
  • Antidepressant pharmacokinetics and pharmacodynamics are influenced by genetic factors, such as cytochrome P450 (CYP) and multidrug resistance (MDR) gene polymorphisms.
  • Existing pharmacogenetic data from depression studies may not directly apply to anxiety disorders.

Purpose of the Study:

  • To review the current state of pharmacogenetic research relevant to anxiety disorders.
  • To highlight the potential of pharmacogenomics in personalizing anxiety disorder treatment.
  • To identify the need for further clinical studies.

Main Methods:

  • Literature review of existing pharmacogenetic and genomic studies.

Related Experiment Videos

  • Analysis of genetic polymorphisms in drug-metabolizing enzymes (e.g., CYP family) and transporters (e.g., MDR1).
  • Evaluation of gene-gene and gene-drug interactions relevant to antidepressant therapy.

    • Main Results:

    • Genetic variations in CYP enzymes and MDR1 influence antidepressant drug pharmacokinetics.
    • Polymorphisms in serotonergic pathway genes affect antidepressant response in depression, but extrapolation to anxiety disorders requires further investigation.
    • Current pharmacogenetic data for anxiety disorders is limited.

    Conclusions:

    • Pharmacogenomics holds significant potential for optimizing anxiety disorder pharmacotherapy.
    • Future psychiatric treatment may involve individualized drug selection and dosage based on genetic profiles.
    • Clinical studies are essential to validate the application of pharmacogenetics in anxiety disorders, aiming to minimize adverse drug reactions and improve treatment outcomes.